The team from Salk Institute and UC San Diego believe a unique cell surface sugar may be able to slow metastasis in pancreatic cancer.
A new study from the Salk Institute and UC San Diego has identified a unique sugar called HSAT (antithrombin-binding heparan sulfate) may slow tumor progression and metastasis in pancreatic ductal adenocarcinoma, the most common pancreatic cancer.
Pancreatic cancer has the highest mortality rate of all major cancers and is difficult to catch and treat early, allowing the cancer to metastasize, or spread, throughout the body.
The study, published Sept 16 in Journal of Clinical Investigation, collected data from patient and mouse samples that showed HSAT is expressed by cells in the pancreas in earlier stages of cancer progression but this expression drops in later stages.
The researchers believe boosting HSAT levels could therefore slow the cancer metastasis, leading to better survival rates.
The study also found that HSAT was detectable in cancer patients’ plasma, making it potentially useful as a biomarker to help catch and track pancreatic cancer.
Understanding pancreatic cancer’s basic biology is critical to prevention or cure, co-senior author Dannielle Engle, assistant professor and holder of the Helen McLoraine Developmental Chair at Salk, said in a press release.
“We discovered that HSAT is actually much more prevalent in the body than was previously understood, especially in cancer, and that it plays an important role in protecting against pancreatic cancer progression,” Engle said.
HSAT was previously thought to be rare in the body, according to study first and co-corresponding author Thomas Mandel Clausen, an associate research scientist at UCSD at the time of the study.
“But we observed that pancreatic ductal adenocarcinoma cells express a high level of a key protein involved in forming HSAT, so we thought perhaps these tumors would express HSA,” he said, adding the team was surprised to find an abundance of HSAT in cells in multiple organs.
The researchers further discovered that patients with more HSAT in their tumors appeared to live longer, suggesting that the molecule may play a protective role in pancreatic cancer.
“An intervention that increases heparan sulfate levels to produce more HSAT could be an effective way to … slow cancer metastasis,” Engle said.
